Randomized trial evaluates efficacy and safety of teprotumumab in Japanese patients with active thyroid eye disease, suggesting its potential benefits.
Alushaj E, Berman G, Mollan SP, Simpson SM, Lowe M. Infographic: teprotumumab for thyroid-associated ophthalmopathy. Eye. 2026. https://doi.org/10.1038/s41433-026-04336-0 . Alushaj E, Lowe M, Mollan SP, Simpson SM, Berman G. Infographic: teprotumumab for the treatment of active thyroid eye disease. Eye. 2026. https://doi.org/10.1038/s41433-026-04432-1 . Alushaj E, Berman G, Lowe M, Mollan SP, Simpson SM. Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. Eye. 2026. https://doi.org/10.1038/s41433-026-04696-7 . Hiromatsu Y, Ishikawa E, Kozaki A, Takahashi Y, Tanabe M, Hayashi K, et al. A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac. 2025;55:101464. https://doi.org/10.1016/j.lanwpc.2025.101464 . Article PubMed PubMed Central Google Scholar Download references
No takes yet. Share an insight, caveat, or question.
Alushaj et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: